Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal (A, C, Y, W) conjugate vaccine + diphtheria + tetanus + acellular pertussis + inactivated poliovirus + hepatitis B + haemophilus influenzae type b vaccine
- Development stage
- Unknown
- Lead developer
- Parent
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MenACYW-DTaP-IPV-Hib-HepB (SP0230) is an investigational, multi-antigen combination vaccine developed by Sanofi to streamline the pediatric immunization schedule. It integrates protection against seven major pathogens: Neisseria meningitidis (serogroups A, C, Y, and W), Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, poliovirus (types 1, 2, and 3), hepatitis B virus, and Haemophilus influenzae type b. The vaccine utilizes a combination of toxoids, inactivated viruses, recombinant proteins, and polysaccharide-protein conjugates (likely using tetanus toxoid as the carrier). By combining these components into a single injection, the vaccine aims to reduce the number of shots required during infancy, thereby improving parental adherence to vaccination schedules and increasing coverage for invasive meningococcal disease. It is currently undergoing Phase 3 clinical evaluation to demonstrate safety and immunologic non-inferiority compared to separately administered licensed vaccines.
- Other names
- MenACYW-DTaP-IPV-Hib-HepB vaccineSP0230SP-0230SP 0230Heptavalent combination vaccine
02
Targets
FIM2/3 (Bordetella pertussis fimbriae type 2 and 3)Diphtheria toxinFHA (Filamentous hemagglutinin)PRNP (Cellular Prion Protein)HBsAg (Hepatitis B surface antigen)NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)PRN (Pertactin)WPV3 (Poliovirus type 3 capsid protein)ETV6 (ETS variant transcription factor 6)TT (Tetanus toxoid)Fimbrial antigen type 3
Beyond the preview
Go deeper on meningococcal (A, C, Y, W) conjugate vaccine + diphtheria + tetanus + acellular pertussis + inactivated poliovirus + hepatitis B + haemophilus influenzae type b vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal (A, C, Y, W) conjugate vaccine + diphtheria + tetanus + acellular pertussis + inactivated poliovirus + hepatitis B + haemophilus influenzae type b vaccine.